T and B cells have been implicated in hypertension, but the mechanisms by which they produce a coordinated response is unknown. T follicular helper (Tfh) cells that produce interleukin 21 (IL21) promote germinal center (GC) B cell responses leading to immunoglobulin (Ig) production. Here we investigate the role of IL21 and Tfh cells in hypertension. In response to angiotensin (Ang) II-induced hypertension, T cell IL21 production is increased, and Il21 -/-mice develop blunted hypertension, attenuated vascular end-organ damage, and decreased interleukin 17A (IL17A) and interferon gamma production. Tfh-like cells and GC B cells accumulate in the aorta and plasma IgG1 is increased in hypertensive WT but not Il21 -/-mice. Furthermore, Tfh cell deficient mice develop blunted hypertension and vascular hypertrophy in response to Ang II infusion. Importantly, IL21 neutralization reduces blood pressure (BP) and reverses endothelial dysfunction and vascular inflammation. Moreover, recombinant IL21 impairs endotheliumdependent relaxation ex vivo and decreases nitric oxide production from cultured endothelial cells. Finally, we show in humans that peripheral blood T cell production of IL21 correlates with systolic BP and IL17A production. These data suggest that IL21 may be a novel therapeutic target for the treatment of hypertension and its micro-and macrovascular complications.
INTRODUCTION
Hypertension affects nearly one-half of all adults in the United States (1) . As a key contributor to vascular disease, chronic kidney disease, and heart failure, hypertension is the leading risk factor for global mortality (2) . Unfortunately, nearly 50% of people with hypertension have uncontrolled blood pressures despite current pharmacological therapies, highlighting the need for a better understanding of the pathophysiology of this disease and identification of novel therapeutic targets (3).
A potential role for immune cells and elevated serum immunoglobulins in hypertension was noted over 50 years ago (4, 5) , but we are still far from understanding the key immune cell subsets and pathways that lead to hypertension and hypertensive end-organ damage. In 2007, Guzik et al. demonstrated that mice deficient in T and B cells develop blunted Ang II-induced hypertension, with the hypertensive response restored by adoptive transfer of T cells (6) . Our group and others demonstrated pathogenic effects of specific T cell subsets, most notably interleukin 17A (IL17A) producing Th17 cells and interferon gamma (IFNg) producing Th1/Tc1 cells, and protective effects of T regulatory (Treg) cells in hypertension (7) . IL17A and IFNg induce vascular dysfunction, glomerular injury, and renal salt and water reabsorption (7, 8) . In 2015, Chan et al. demonstrated that pharmacological or genetic depletion of B cells protects against experimental hypertension (9) . The specific T helper subset that provides help to B cells is T follicular helper (Tfh) cells that produce IL21, and yet the role of IL21 and Tfh cells in hypertension is unknown. Importantly, in addition to promoting Th17 and Th1 cells, IL21 from Tfh cells drives a germinal center (GC) reaction in secondary or tertiary lymphoid organs resulting in GC B cell immunoglobulin (Ig) class switching (e.g. IgM ® IgG) and high affinity antibody production (10) (11) (12) (13) . Whether hypertension is associated with a germinal center response is not known.
Here we report the novel finding that hypertension is associated with increased Tfh and GC B cells in the aorta and increased GC B cells in secondary lymphoid organs along with increased plasma IgG1. Using genetic and/or pharmacological inhibition of IL21 and Tfh cells, we demonstrate a previously undefined role for IL21 in hypertension pathogenesis and vascular dysfunction, suggesting that IL21 and Tfh cells may serve as novel therapeutic targets for this disease.
RESULTS

Hypertension is associated with increased CD4
+ T cell production of IL21, and IL21 deficiency attenuates the rise in blood pressure (BP) Figure 1C ) and invasive radio telemetry ( Figure 1D ). Diastolic BP was similarly reduced in Il21 -/-mice compared to WT controls with no change in heart rate ( Figures 1E and 1F ). To determine if there are gender differences in the effect of IL21 on hypertension, we studied female mice and found that both the hypertensive response and effect of IL21 deficiency were similar to those observed in male mice ( Figure S1A ). To confirm that the BP protection was not unique to the Ang II model, we investigated the effect of IL21 deficiency in a salt-sensitive hypertension model characterized by uninephrectomy, implantation of a deoxycorticosterone acetate (DOCA) pellet, and 1% NaCl in the drinking water and observed a similar 20 mmHg reduction in systolic BP ( Figure S1B ). All further studies were conducted in male mice using the Ang II hypertension model.
Loss of IL21 protects against Ang II-induced vascular remodeling and endothelial dysfunction.
Hypertension is associated with increased aortic collagen deposition, vascular smooth muscle cell hypertrophy, and microvascular endothelial dysfunction. To determine the effect of IL21 deficiency on vascular remodeling and endothelial function, WT and Il21 -/-mice were infused with vehicle or Ang II for 4 weeks. Importantly, Il21 -/-mice thoracic aortas exhibit significantly less aortic collagen deposition and reduced medial hypertrophy (Figures 2A-C) . Representative aortic cross-sections are shown in Figures 2A-B with quantification in Figure 2C . Resistance artery endothelial function was assessed by measuring endothelium-dependent and -independent relaxation of third-order mesenteric arterioles. A modest baseline impairment in endotheliumdependent relaxation to acetylcholine (Ach) is present in Il21 -/-mesenteric arterioles, but the key finding is that the Il21 -/-mice are completely protected from further endothelial dysfunction in response to Ang II infusion, while WT vessels exhibit a severe impairment in endotheliumdependent relaxation in response to Ang II. There was no effect of Ang II or IL21 deficiency on endothelium-independent relaxation to sodium nitroprusside (SNP) ( Figure 2D ). Since vascular reactivity can be mediated by alterations in superoxide levels, we measured superoxide production in isolated mesenteric arterioles. Interestingly, Il21 -/-mice exhibit increased superoxide levels at baseline, consistent with their baseline impairment in vascular reactivity, but no further increase in response to Ang II infusion. In contrast, WT mice exhibit a marked upregulation of superoxide production in response to Ang II-induced hypertension ( Figure 2E ).
IL21 deficiency blunts early vascular infiltration of natural killer (NK) T cells and macrophages.
We previously showed that during the initial phase of Ang II-induced hypertension (day 7 Figure S2 . Macrophages and neutrophils were gated from CD11b + cells and NK T cells were gated from CD3 + cells ( Figure S2 ). Representative biaxial flow cytometry dot plots are shown for each group ( Figure 3A) . We found that Ang IIinduced hypertension is associated with an early increase in total leukocytes, NK T cells, and macrophages, and this increase is abrogated in Il21 -/-mice ( Figure 3B ). Neutrophils were not increased by Ang II infusion or affected by IL21 deficiency ( Figure 3B) . Thus, IL21 deficiency protects from early innate immune cell infiltration into the aorta. Figure 4C ). We previously showed that hypertension is associated with increased T cell production of the pro-inflammatory cytokines IL17A and IFNg (18, 19) . IL21 can potentially modulate the balance of Th17, Th1, and Treg subsets in disease (11, 20) . Therefore, we investigated the effect of IL21 deficiency on T cell production of IL17A, IFNg, and IL10 in hypertension. Consistent with our prior results, we detected an increase in CD4 + T cell production of IL17A and CD8 + T cell production of IFNg in splenic T cells cultured from hypertensive vs normotensive mice, and these hypertension-induced changes were completely abrogated in Il21 -/-mice. Neither Ang II nor IL21 deficiency affected CD4 + T cell production of IL10 ( Figure 4D ). 
Hypertension induces GC
Hypertensive DCs induce Tfh cell polarization, and Tfh cells play a critical role in hypertension.
Hypertensive Figure 7A) . Importantly, anti-IL21 treatment restores endothelium-dependent relaxation to Ach to levels comparable with vehicle infused WT animals ( Figure 7B ). Endotheliumindependent relaxation to SNP was similar in both groups ( Figure S7 ). In addition, anti-IL21 treatment decreases aortic inflammatory cells, including Tph, Tfh, and GC B cells, to levels comparable to vehicle infused WT animals ( Figure 7E) . Thus, inhibition of IL21 lowers BP and reverses endothelial dysfunction and vascular inflammation.
Recombinant IL21 impairs endothelium-dependent relaxation ex vivo and decreases nitric oxide
production from cultured human aortic endothelial cells. To determine whether IL21 has direct vascular effects independent of T and B cells, we isolated third order mesenteric arterioles from WT mice and assessed endothelium-dependent relaxation to Ach before and after 1 hour of incubation with recombinant IL21 protein (100 ng/ml) or vehicle (PBS). IL21 but not vehicle treatment resulted in impaired endothelium-dependent relaxation (Figures 8A-B) . We have previously shown that vascular NO levels are decreased in WT mice in response to Ang II infusion (19) . To determine the effect of IL21 on endothelial NO production, we cultured human aortic endothelial cells (HAECs) with vehicle or recombinant IL21 and assessed NO production using flow cytometry with the DAF-FM dye. IL21 decreased NO production from these cells ( Figure   8C ). Thus, IL21 has direct detrimental effects on the vessel wall independent of alterations in T and B cells.
CD4 + T cell production of IL21 correlates with systolic BP and IL17A in humans.
To determine the relevance of our findings to human hypertension, we quantified IL21 and IL17A production from cultured CD4 + T cells isolated from the peripheral blood of 37 subjects ( Figure 9A and Table S1 ).
Systolic BP (SBP) was measured on the day of blood draw and significantly correlated with IL21 levels ( Figure 9B ). In addition, when stratified by SBP less than or greater than or equal to 130 mmHg, IL21 production from CD4 + T cells was significantly higher in those with SBP greater than or equal to 130 mmHg ( Figure 9C ). In this sample set, IL21 levels did not differ significantly between blacks and whites or males and females and did not correlate with BMI or age.
Furthermore, T cell production of IL21 strongly correlated with IL17A production (Figure 9D) , and this correlation remained significant in multivariate analysis after controlling for race, gender, age, and BMI. This finding suggests that the same or similar cells are producing IL21 and IL17A in human hypertension and/or that one cytokine strongly regulates the other. As described above, IL21 is known to promote IL17A production. Taken together, these data suggest that IL21 and the cells that produce it are an attractive therapeutic target for hypertension and its vascular complications. IL21 is a pleiotropic cytokine with effects on innate and adaptive immune cells as well as nonimmune cells (10, 27) . IL21 has been shown to promote Th17 and Th1 cells and inhibit Treg cells (11, 20) . We and others demonstrated that hypertension is associated with an increase in IL17A
DISCUSSION
and IFNg production, and that these cytokines play important roles by modulating renal sodium transporters, vascular fibrosis, and endothelial function (20, 28, 29) . Here, we show that loss of IL21 abrogates hypertension-induced T cell production of IL17A and IFNg. IL21 is also the most potent cytokine known to induce GC B cell proliferation and differentiation into antibody secreting plasma cells (20) . In keeping with this, we found that hypertension is associated with increased accumulation of GC-like cells in the vasculature and secondary lymphoid organs in an IL21 dependent manner. Finally, we show that IL21 has direct effects on vascular endothelial cells, altering bioavailability of nitric oxide and promoting endothelial dysfunction. Future studies are needed to determine mechanisms by which IL21 alters superoxide and NO levels and to investigate whether IL21 has direct effects on vascular smooth muscle cells and fibroblasts to increase chemokine expression and collagen synthesis. In line with this, it has been shown in inflammatory bowel disease that colonic myofibroblasts and epithelial cells respond to IL21 by secreting matrix metalloproteases and chemokines that recruit other inflammatory cells (27) .
These potential effects of IL21 in hypertension are not mutually exclusive, and thus we propose In summary, we show that both experimental and human hypertension is associated with increased CD4 + T cell production of IL21. Mice deficient in IL21 exhibit blunted hypertension and vascular end-organ dysfunction. Pharmacological inhibition of IL21 after the onset of hypertension lowers BP and reverses endothelial dysfunction and vascular inflammation. Furthermore, hypertension is associated with increased aortic Tfh and GC B cells, and Tfh cell deficiency protects from chronic Ang II-induced hypertension. To our knowledge, this is the first study implicating a GC reaction in hypertension and suggests that inhibition of IL21 or specific depletion of IL21 producing cells may be a novel therapeutic strategy for the treatment of hypertension and its micro-and macrovascular complications.
METHODS
Animals and Experimental Hypertension
Wild type C57BL/6J mice, CD4-cre transgenic mice (Tg CD4cre ), and Bcl6 flox/flox mice were purchased from Jackson Laboratories. Il21 -/-mice were generated as previously described (35) . These mice were backcrossed greater than 10 generations to C57BL/6J mice. Age and gender matched mice between 10-12 weeks of age were used. Experimental hypertension was induced using the Ang 
Blood pressure (BP) measurement
BP was measured twice weekly and averaged using a noninvasive tailcuff platform (Hatteras) or invasively by carotid radiotelemetry as previously described (14) . Mice were allowed to recover for 10-14 days post-telemetry implantation prior to obtaining baseline BPs and implantation of osmotic minipumps.
Murine T cell isolation, culture, and cytokine quantification
Spleen homogenates were filtered through a 40 µm cell strainer followed by depletion of red blood cells using red blood cell lysis buffer (eBioscience). CD4 + and CD8 + T cells were isolated from splenic single-cell suspensions using Miltenyi cell separation kits according to the manufacturer's instructions and sorted using an AutoMACS magnetic cell sorter (Miltenyi Biotec). Cells were plated in RPMI 1640 media + 10% FBS+ 1% penicillin/streptomycin + 50µM b-mercaptoethanol at a density of 200,000 cells/100µl on a non-tissue culture treated 96-well plate coated with mouse anti-CD3 (2µg/ml) and mouse anti-CD28 (2µg/ml) antibodies (BD Biosciences) for 72hours.
Murine IL17A, IFNg, interleukin 10 (IL10) and IL21 were measured from cell culture supernatants by ELISA Ready-Set-Go! Kits (eBioscience).
RNA isolation and qRT-PCR
RNA was isolated from cells using an RNeasy mini kit (Qiagen) according to the manufacturer's instructions. Total RNA concentration was measured using a DS-11 spectrophotometer (DeNovix). A High-Capacity cDNA Reverse Transcription kit (Applied Biosystems) was used according to the manufacturer's instructions to make cDNA. The Taqman assay system (Thermo Fisher Scientific) was used to detect Il21, Bcl6, and Gapdh (endogenous control). Relative quantification was determined using the comparative CT method with data normalized to Gapdh and calibrated to the average of the control group. Picrosirius Red as previously described (19, 36) . Slides were imaged at 20x using a Leica SCN400 Slide Scanner and acquired and exported using Leica Biosystems.
Immunohistochemistry, histological staining, and imaging
Vascular reactivity studies
Isometric tension studies were conducted using 2-mm segments of third-order mesenteric arterioles dissected free of perivascular fat. Studies were performed in a small vessel horizontal wire myograph (Danish Myo Technology, models 610M and 620M) as previously described (14) .
Vessels were pre-constricted with norepinephrine prior to treatment with increasing doses of acetylcholine (Ach) or sodium nitroprusside (SNP). For ex vivo IL21 treatment experiments, vessels were incubated with recombinant murine IL21 (100 ng/ml; Peprotech) or vehicle (phosphate buffered saline (PBS)) in the organ chamber for 1 hr between assessments of endothelium-dependent relaxation to Ach.
Mesenteric vessel superoxide measurement
Superoxide levels were measured from mesenteric arterioles by quantification of 2-hydroxyethidium (2-OH Eth) from dihydroethidium (DHE) by high performance liquid chromatography. The 2-OH Eth product specifically reflects the interaction of DHE with superoxide as previously validated (37) .
Fluorescent flow cytometry staining of lymph node and aortic leukocytes
Mesenteric lymph nodes free of surrounding fat were homogenized and filtered through a 40 µm cell strainer. Single-cell suspensions of whole aorta with adjacent perivascular fat were isolated as previously described (38) . Samples were stained for viability and surface markers using the . Staining was performed in 100µl. All antibodies were used at 1:100 dilution. Samples were acquired on a BD FACSCanto II system and analyzed using CytoBank. Gates were applied using fluorescence minus one (FMO) controls. A known quantity of counting beads (123count eBeads, eBioscience) were added to each sample prior to acquisition. Results were normalized using the bead count.
Antibody treatments
Mice were implanted with 28-day osmotic minipumps containing Ang II. After 14 days of Ang II infusion, mice were randomized to either an isotype control group (eBioscience, rat IgG2 k isotype control functional grade purified, clone eBRa) or mouse anti-IL21 treatment group (eBioscience, anti-mouse anti-IL21 functional grade purified, clone FFA21). Treatment was administered by intraperitoneal injection with 100µg of antibody twice a week for the last 2 weeks of Ang II infusion (days 16, 19, 22, and 25) . This regimen was chosen based on prior studies (39) .
Plasma immunoglobulin isolation and quantification
Mice were euthanized, and whole blood was collected by direct cardiac puncture into an EDTA coated syringe. Blood was immediately centrifuged, and plasma stored at -80°C. Plasma immunoglobulin was quantified using LEGENDplex Mouse Immunoglobulin Isotyping Panel (Biolegend) according to the manufacturer's instructions.
Dendritic cell (DC)-CD4 + T cell co-culture
Splenic single cell suspensions were generated as described above. 
Statistics
All data are expressed as mean ± SEM or as box and whisker plots as indicated. Data were analyzed in GraphPad Prism or R using Student's t-test (for 2 group comparisons) or 2-way ANOVA (for multiple group comparisons). Nonparametric 2 group data were analyzed by Mann Whitney test. Vascular relaxation studies were compared using area under the curve analysis.
Human cytokine data were log transformed for Pearson's correlation analysis. P < 0.05 was considered significant.
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